📋 Clinical Overview

Pegylated Interferon Alpha 2B is a long-acting, covalent conjugate of recombinant human interferon alpha-2b with a single, linear 12 kDa polyethylene glycol (PEG) chain. This pegylation significantly prolongs its half-life, reduces immunogenicity, and allows for once-weekly subcutaneous administration. It is a potent immunomodulator and antiviral agent, primarily used in the management of chronic hepatitis B and C infections in the Indian context. It exerts its effects by binding to specific cell surface receptors, activating the JAK-STAT signaling pathway, leading to the expression of interferon-stimulated genes (ISGs) that inhibit viral replication and modulate immune responses.

💊 Dosage & Administration

Adult: Hepatitis C: 1.5 mcg/kg body weight subcutaneously once weekly. Often used in a weight-based dosing strategy (e.g., 50mcg for patients <40kg, 80mcg for 40-50kg, etc.). The 50mcg vial is part of this weight-based regimen. Hepatitis B: 1.0 mcg/kg subcutaneously once weekly OR 50mcg once weekly fixed dose for patients weighing <40kg. Duration: 24-48 weeks for HCV, 48 weeks for HBV, as per protocol.
Pediatric: Not routinely recommended for children under 3 years. For children ≥3 years with chronic hepatitis C: 60 mcg/m2 body surface area subcutaneously once weekly, with Ribavirin. Use requires specialist pediatric hepatologist supervision.
Renal Adjusment: Mild to Moderate impairment (CrCl 30-80 mL/min): Monitor closely. Severe impairment (CrCl <30 mL/min) or ESRD on hemodialysis: Contraindicated or use with extreme caution at reduced doses (e.g., 25-50mcg weekly) with intensive monitoring for toxicity.
Hepatic Adjusment: Contraindicated in decompensated cirrhosis (Child-Pugh B & C). In compensated cirrhosis (Child-Pugh A), use standard doses with close monitoring for hepatic decompensation.
Instruction: For subcutaneous use only. Provided as a lyophilized powder in a single-use vial. Reconstitute strictly aseptically with 0.7 mL of supplied Sterile Water for Injection. Gently swirl, do not shake. The resulting solution concentration is approximately 70 mcg/mL. Draw the appropriate volume (e.g., ~0.71 mL for a 50mcg dose) into a syringe. Inject SC into the thigh or abdomen, rotating injection sites. Use immediately after reconstitution. Discard any unused portion.

⚠️ Contraindications

Known hypersensitivity to interferon alpha-2b, polyethylene glycol (PEG), or any component
Autoimmune hepatitis or history of severe autoimmune disease
Decompensated liver disease (Child-Pugh Class B & C) prior to or during treatment
Severe pre-existing psychiatric conditions (e.g., severe depression, suicidal ideation, psychosis)
Concurrent use with Telbivudine (risk of severe peripheral neuropathy)

🔬 Mechanism of Action

Peginterferon alfa-2b binds to specific, high-affinity cell-surface receptors (IFNAR1 and IFNAR2) present on most human cells. This binding activates the intracellular JAK-STAT (Janus kinase-signal transducer and activator of transcription) signaling pathway. Activation leads to the transcription and translation of over 300 Interferon-Stimulated Genes (ISGs). The proteins produced have multiple effects: 1) Direct antiviral activity via induction of enzymes like 2',5'-oligoadenylate synthetase (2-5 OAS) and protein kinase R (PKR) which inhibit viral RNA translation and degrade viral RNA. 2) Immunomodulation by enhancing antigen presentation (upregulation of MHC class I), activating natural killer (NK) cells and cytotoxic T-lymphocytes, and modulating cytokine production.

🤕 Side Effects

Influenza-like symptoms (fever, chills, headache, myalgia, arthralgia - often managed with pre-dose paracetamol)
Fatigue, asthenia
Injection site reactions (erythema, pain, swelling)
Anorexia, nausea
Alopecia (reversible)
Mild psychiatric symptoms (irritability, insomnia)

🤰 Special Populations

Pregnancy: Pregnancy Category C. Animal studies show abortifacient effects. In humans, risk of fetal harm is unknown. Use only if potential benefit justifies potential fetal risk. MUST be used in combination with effective contraception (usually with Ribavirin, which is Category X and mandates two forms of contraception).

Lactation: Not known if excreted in human milk. Due to potential for serious adverse reactions in nursing infants, a decision should be made to discontinue nursing or discontinue the drug.

Alcohol: Alcohol consumption is strongly discouraged during therapy for hepatitis. It can exacerbate liver disease, increase hepatotoxicity risk, and reduce treatment adherence.

Driving: May cause fatigue, dizziness, and confusion. Patients should be cautioned about driving or operating machinery, especially during initial therapy or if experiencing such symptoms.

🔄 Drug Interactions

Ribavirin: Additive antiviral efficacy against HCV, but also additive risk of hemolytic anemia. Mandatory combination in many HCV regimens. Major
Telbivudine: Increased risk of severe peripheral neuropathy. Concomitant use is contraindicated. Contraindicated
Zidovudine (AZT): Increased risk of severe neutropenia and anemia. Avoid combination or monitor blood counts intensively. Major
Theophylline: Peginterferon may reduce the clearance of theophylline, increasing its serum levels and risk of toxicity. Monitor theophylline levels. Moderate
Methadone: May increase methadone plasma levels, potentially leading to increased opioid effects. Monitor for sedation and respiratory depression. Moderate
Warfarin: May alter INR; increased monitoring of INR is required. Moderate
Live Vaccines: Theoretical risk of enhanced vaccine-related infections due to immunomodulation. Avoid. Major

🔁 Alternatives to Pegasis (Note: This is Peginterferon alfa-2a, a different molecule)

Same composition (Pegylated Interferon Alpha 2B (50mcg)), different brands:

PegIntron Pegferon Reiferon Peg